RecruitingProstate CancerOligometastatic Disease
TERPS Trial for de Novo Oligometastic Prostate Cancer
Eligible age
18+ yrs
Accepts
Men
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Sponsor: University of Maryland, Baltimore
You may qualify if…
- ✓ 1. Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone or soft tissue (with at least one bone metastasis) develop within the past 6-months that are seen on imaging. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or PSMA PET-CT scan.
- ✓ 1. CT or MRI scan within 6 months of enrollment
- ✓ 2. Bone scan within 6 months of enrollment
- ✓ 3. Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan)
- ✓ 2. Histologic confirmation of malignancy (primary or metastatic tumor).
- ✓ 3. Patient may have had prior systemic therapy and/or ADT associated with treatment within 9-months of enrollment.
- ✓ 4. PSA \> 0.5 but \<100.
- ✓ 5. Patient must be ≥ 18 years of age.
You may not qualify if…
- ✕ 1. Castration-resistant prostate cancer (CRPC).
- ✕ 2. Prior radiation therapy to an overlapping site of a target lesion that would preclude further radiation therapy
- ✕ 3. Spinal cord compression or impending spinal cord compression.
- ✕ 4. Suspected pulmonary and/or liver metastases (greater \>10 mm in largest axis).
- ✕ 5. Patient receiving any other investigational agents.
- ✕ 6. Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist .
- ✕ 7. Unable to lie flat during or tolerate PET/MRI, PET/CT or SABR.
- ✕ 8. No radiographical evidence of cranial metastasis.
Where it's recruiting
California
La Jolla
Kansas
Kansas City
Maryland
Baltimore · Bel Air · Columbia · Glen Burnie
Pennsylvania
Philadelphia · Pittsburgh
Virginia
Midlothian
Source: ClinicalTrials.gov · NCT05223803 · last updated 2026-06-03